Clinical Trial Agreements Information Sheet

University of Kentucky faculty and staff participate in numerous clinical trial projects to study investigational drugs or devices. These studies are usually funded by pharmaceutical companies and are an important part of the process to assure the safety and efficacy of the drug or device, obtain Food and Drug Administration (FDA) approval and bring a product to market.

The Office of Sponsored Projects Administration (OSPA) is responsible for reviewing, negotiating and legally accepting agreements from external funding sources. The resolution of many contractual issues requires coordination between the external funding source, Investigator and OSPA; the involvement of each party is essential to a successful contractual arrangement with mutually acceptable terms. Investigators should provide OSPA with a copy of the proposed agreement and a company contact person as early in the process as possible.

Although each document is reviewed on a case-by-case basis, there are a number of key issues which are common to most clinical trial agreements. These are summarized below.

CONFIDENTIALITY 
It is often necessary for the sponsoring company to provide information of a proprietary nature to the Investigator and it is important to the company's business interests that the confidentiality of this information be protected. Written confidential information should be stamped as such and oral communication should be reduced to writing and stamped "confidential." Investigators and other University employees involved in the project may be required to sign a separate statement indicating they understand and will comply with the obligation to maintain confidentiality. Access to confidential information (including the protocol) must be strictly controlled and each Investigator should have a plan for assuring control.

CONFLICT OF INTEREST 
The University’s Conflict of Interest policy is applicable to all sponsored research. Investigators are required to complete a "Disclosure of Financial Interest Form" for each proposed study.

FACILITIES AND ADMINISTRATIVE COSTS
Facilities and Administrative (F&A) costs for industry funded human clinical studies are currently assessed at the rate of 21.5% of total cash received. This is based on the actual calculated off-campus research rate of 27.4% of Total Direct Costs. To estimate F&A costs when the direct costs are known, add 27.4% of the direct costs. The sum of these two figures is the per-patient amount. Example: If $785 is needed to cover direct costs, 27.4% or $215 should be added for F&A, bringing the total to $1000 per patient.  For clinical trials that are federally funded, F&A is generally calculated using the current federally capped off-campus research rate of 26% applied to a Modified Total Direct Cost base.  If you have any questions as to how F&A is to be calculated for a specific clinical trial, please contact your College Grants Officer or Research Administrator.

FUNDING 
Clinical studies are usually funded on a per-patient basis with provisions for pro-rated payment for patients who do not complete the study. All costs necessary to conduct the study, including salaries, supplies and Facilities and Administrative costs, should be considered when determining the fixed per-patient amount. It is also desirable to obtain an initial, non-refundable payment for the administrative efforts of starting the project and recruiting subjects.

GENERIC DRUG ENFORCEMENT ACT 
Many agreements include a clause which requires a certification that the Principal Investigator and others participating in the study are not debarred, and have never been debarred, under the Generic Drug Enforcement Act of 1992. The University must notify the company of any debarment or threat of debarment occurring during the term of the study. Investigators and others involved in the study may be required to sign such a certification.

GOVERNING LAW 
Agreements must either be governed by the laws of the State of Kentucky or this provision must be absent from the agreement.

HUMAN SUBJECTS 
The Investigator must obtain approval of the study protocol and informed consent form from theUniversity Institutional Review Board (IRB) before a subject may be enrolled in the study. A sponsoring company usually requires evidence of IRB approval before sending the study drug.

INTELLECTUAL PROPERTY 
The drug or device being tested in the clinical trial is normally owned by the sponsoring company and already covered by patent protection. Although each situation must be reviewed on its own merit, it is the University's general policy that title to inventions arising from projects conducted by faculty, staff or students will be owned by the University. Clinical studies usually afford the sponsoring company the right of first refusal to obtain an exclusive, worldwide, royalty-bearing license to discoveries arising from the conduct of the study.

INDEMNIFICATION 
The sponsoring company, and the actual owner of the study drug or device if an intermediary is involved, must agree to indemnify and hold harmless the University, UKRF, Investigators, trustees, officers, agents and employees from any and all liabilities, claims, actions or suits for personal injury or death arising from the administration of the study drug. The complete indemnification statement will have certain limits and conditions designed to protect both parties.

INSURANCE 
To support the above indemnification the sponsoring company must maintain a sufficient level of insurance.

IRS IDENTIFICATION 
61-6033693 for University of Kentucky Research Foundation

PUBLICATION 
Agreements must allow the Investigator the freedom to publish study results. However, the company may have the right of prior review to identify proprietary information.

RECORDS AND DATA 
The University must retain possession of original data and any medical records generated by the study. The sponsoring company usually provides forms on which to record relevant subject information; the originals of these forms may be forwarded to the company with a copy retained by the University.

REIMBURSEMENT OF SUBJECT INJURY COSTS 
The agreement shall include a provision that the sponsoring company will reimburse  the cost of reasonable and necessary medical expenses incurred by a study subject as a result of participation in the trial, provided such expenses are in no way attributable to negligence on the part of the University.

UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 
Agreements should be made between the sponsoring company and The University of Kentucky Research Foundation (UKRF). UKRF is a non-profit, affiliated corporation of the University of Kentucky through which grants and contracts from external sponsors are received. Agreements from the sponsoring company must be reviewed by OSPA and signed by a UKRF official (seeAR II-1.0-3). Checks from the sponsoring company should be made payable to UKRF.

OTHER CONSIDERATIONS

ACCOUNT NUMBER 
To obtain a University account number for the project the following documentation is required: a fully routed electronic Internal Approval Form ( IAF) and Fixed-Price Agreement Budget FormResearch Financial Interest Disclosure Statement forms, a copy of the study protocol, a signed written agreement between the sponsoring company and UKRF, and Institutional Review Board (IRB) approval. The account budget will be established based on actual cash from the sponsoring company and increased each time payment is received.

ACCOUNT TIME EXTENSION 
When additional time is needed to complete a study the Investigator may send a request to OSPA for an extension of up to six months. An additional six month extension may be approved by Deborah K. Davis, Associate Direction, University of Kentucky Research Foundation. Use the form Prior Approval Request for Revision/Action on Sponsored Project Account.

INTERNAL APPROVAL FORM 
A University Internal Approval Form (IAF) must be completed, signed and provided to OSPA for each clinical study. In addition, a Fixed-Price Agreement Budget Form with Column A completed should be attached to the IAF. Research Financial Interest Disclosure Statement forms are also required.

RESIDUAL BALANCE 
At the conclusion of any fixed-price agreement there may be a cash balance remaining. If expenditures incurred to conduct the study are reasonable in relation to the projected cost and when all costs (direct and Facilities and Administrative Costs) have been properly charged and documented, the cash balance will be made available to the Investigator.

A note regarding other types of agreements: Projects which do not involve human clinical activity are subject to different Facilities and Administrative Cost rates than those noted above. They may also have different administrative requirements such as approval by the Institutional Animal Care and Use Committee (IACUC) if animal subjects are used.

For more information please contact the Office of Sponsored Projects Administration (OSPA) at 257-9420. OSPA has a model agreement available on this page which may be given to a prospective sponsor as an example to be used in whole or in part

University of Kentucky | UK Research
Updated September 6, 2013 | Questions/Corrections to Sean Scott